{"id":276,"date":"2026-02-26T05:46:07","date_gmt":"2026-02-26T02:46:07","guid":{"rendered":"https:\/\/bilimaktuel.com\/?p=276"},"modified":"2026-02-26T05:46:08","modified_gmt":"2026-02-26T02:46:08","slug":"insanlarda-ilk-hucresel-genclestirme-denemesi-basladi","status":"publish","type":"post","link":"https:\/\/bilimaktuel.com\/index.php\/2026\/02\/26\/insanlarda-ilk-hucresel-genclestirme-denemesi-basladi\/","title":{"rendered":"\u0130nsanlarda \u0130lk H\u00fccresel \u201cGen\u00e7le\u015ftirme\u201d Denemesi Ba\u015flad\u0131"},"content":{"rendered":"\n<p>ABD merkezli biyoteknoloji \u015firketi Life Biosciences, geli\u015ftirdi\u011fi deneysel g\u00f6z tedavisi ER-100 i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi\u2019nden (U.S. Food and Drug Administration (FDA)) klinik deneme onay\u0131 ald\u0131. \u015eirketin a\u00e7\u0131klamas\u0131na g\u00f6re bu \u00e7al\u0131\u015fma, insanlarda uygulanan ilk \u201ck\u0131smi epigenetik yeniden programlama\u201d temelli h\u00fccresel gen\u00e7le\u015ftirme denemesi olarak kay\u0131tlara ge\u00e7ti.<\/p>\n\n\n\n<p><br>\ud83d\udd2c <strong>ER-100 Nedir?<\/strong><\/p>\n\n\n\n<p><br>ER-100, h\u00fccrelerin ya\u015flanma s\u00fcrecinde kaybettikleri fonksiyonlar\u0131 geri kazand\u0131rmay\u0131 hedefleyen k\u0131smi epigenetik reprogramlama yakla\u015f\u0131m\u0131n\u0131 kullan\u0131yor.<br>Bu y\u00f6ntemde:<br>H\u00fccre DNA\u2019s\u0131 de\u011fi\u015ftirilmez<br>Ancak genlerin \u00e7al\u0131\u015fma d\u00fczeni (epigenetik yap\u0131) gen\u00e7 h\u00fccrelere benzer bir duruma d\u00f6nd\u00fcr\u00fclmeye \u00e7al\u0131\u015f\u0131l\u0131r<br>Ama\u00e7, h\u00fccreleri tamamen k\u00f6k h\u00fccreye \u00e7evirmek de\u011fil, \u201cdaha gen\u00e7 bir i\u015flevsel seviyeye\u201d getirmektir<br>Bu teknoloji daha \u00f6nce fare ve primat deneylerinde test edilmi\u015fti. \u0130nsanlarda uygulanmas\u0131 ise ilk kez bu \u00e7al\u0131\u015fma ile m\u00fcmk\u00fcn oldu.<\/p>\n\n\n\n<p><strong>Hangi Hastal\u0131klar Hedefleniyor<\/strong>?<\/p>\n\n\n\n<p><br>Deneme do\u011frudan \u201ckozmetik gen\u00e7le\u015fme\u201d de\u011fil; ya\u015fa ba\u011fl\u0131 ciddi g\u00f6z hastal\u0131klar\u0131n\u0131 hedefliyor:<br>A\u00e7\u0131k a\u00e7\u0131l\u0131 glokom<br>Non-arteritik anterior iskemik optik n\u00f6ropati (NAION)<br>Bu hastal\u0131klarda optik sinir h\u00fccreleri hasar g\u00f6r\u00fcr ve mevcut tedaviler hasar\u0131 geri \u00e7eviremez. ER-100 ise h\u00fccre fonksiyonunu yeniden canland\u0131rmay\u0131 ama\u00e7l\u0131yor.<br>\ud83d\udcca Klinik \u00c7al\u0131\u015fma Hangi A\u015famada?<br>FDA, ER-100 i\u00e7in IND (Investigational New Drug) ba\u015fvurusunu onaylad\u0131.<br>Deneme \u015fu anda Faz 1 a\u015famas\u0131nda.<br>\u00d6ncelikli ama\u00e7: g\u00fcvenlik ve tolere edilebilirlik de\u011ferlendirmesi.<br>\u0130lk kat\u0131l\u0131mc\u0131 kay\u0131tlar\u0131n\u0131n 2026\u2019n\u0131n ilk \u00e7eyre\u011finde ba\u015flamas\u0131 planland\u0131.<br>\u0130lk g\u00fcvenlik verilerinin y\u0131l sonuna kadar a\u00e7\u0131klanmas\u0131 bekleniyor.<br>Faz 1 a\u015famas\u0131nda genellikle:<br>Az say\u0131da hasta yer al\u0131r<br>\u0130lac\u0131n g\u00fcvenli\u011fi \u00f6l\u00e7\u00fcl\u00fcr<br>Etkinlik verileri s\u0131n\u0131rl\u0131d\u0131r<\/p>\n\n\n\n<p><br>\ud83e\uddec <strong>Neden Tarihi Bir Ad\u0131m?<\/strong><br>Bu \u00e7al\u0131\u015fma, ya\u015flanmay\u0131 biyolojik d\u00fczeyde geri \u00e7evirme iddias\u0131n\u0131 insanlarda test eden ilk resmi FDA onayl\u0131 klinik giri\u015fimlerden biri olmas\u0131 nedeniyle dikkat \u00e7ekiyor.<br>Daha \u00f6nce benzer \u00e7al\u0131\u015fmalar:<br>Farelerde g\u00f6rme fonksiyonunu iyile\u015ftirmi\u015fti<br>Primat modellerinde h\u00fccresel ya\u015f g\u00f6stergelerinde gerileme g\u00f6stermi\u015fti<br>Ancak insanlarda sonu\u00e7 al\u0131nmadan \u201cgen\u00e7le\u015fme ger\u00e7ekle\u015fti\u201d demek m\u00fcmk\u00fcn de\u011fil.<\/p>\n\n\n\n<p><br>\u26a0\ufe0f <strong>Uzmanlar\u0131n Uyar\u0131s\u0131<\/strong><br>Bilim insanlar\u0131 \u015fu noktaya dikkat \u00e7ekiyor:<br>Bu erken a\u015fama bir g\u00fcvenlik denemesi<br>Ba\u015far\u0131 garantisi yok<br>Uzun vadeli etkiler hen\u00fcz bilinmiyor<br>H\u00fccresel yeniden programlama teorik olarak t\u00fcm\u00f6r riskleri gibi ciddi sorular bar\u0131nd\u0131r\u0131yor<\/p>\n\n\n\n<p><br>\ud83d\udcc5 <strong>Bundan Sonra Ne Olacak?<\/strong><br>E\u011fer Faz 1 g\u00fcvenli bulunursa:<br>Faz 2: Daha geni\u015f hasta grubunda etkinlik de\u011ferlendirmesi<br>Faz 3: B\u00fcy\u00fck \u00f6l\u00e7ekli kar\u015f\u0131la\u015ft\u0131rmal\u0131 klinik \u00e7al\u0131\u015fma<br>FDA onay\u0131 ve potansiyel ticarile\u015fme<br>Bu s\u00fcre\u00e7 genellikle 5\u20138 y\u0131l s\u00fcrebilir.<\/p>\n\n\n\n<p><br><br>ER-100, ya\u015flanmay\u0131 geri \u00e7evirme ara\u015ft\u0131rmalar\u0131nda insan a\u015famas\u0131na ge\u00e7ilmi\u015f ilk ciddi ad\u0131mlardan biri olarak g\u00f6r\u00fcl\u00fcyor.<br>Ancak \u015fu an i\u00e7in:<br>Gen\u00e7le\u015fme kan\u0131tlanm\u0131\u015f de\u011fil<br>\u00c7al\u0131\u015fma hen\u00fcz ba\u015flang\u0131\u00e7 a\u015famas\u0131nda<br>Klinik sonu\u00e7lar bekleniyor<br>Bilim d\u00fcnyas\u0131 \u015fimdi 2026 sonunda a\u00e7\u0131klanacak ilk g\u00fcvenlik verilerine odaklanm\u0131\u015f durumda.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ABD merkezli biyoteknoloji \u015firketi Life Biosciences, geli\u015ftirdi\u011fi deneysel g\u00f6z tedavisi ER-100 i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi\u2019nden (U.S. Food and Drug Administration (FDA)) klinik deneme onay\u0131 ald\u0131. \u015eirketin a\u00e7\u0131klamas\u0131na g\u00f6re bu \u00e7al\u0131\u015fma, insanlarda uygulanan ilk \u201ck\u0131smi epigenetik yeniden programlama\u201d temelli h\u00fccresel gen\u00e7le\u015ftirme denemesi olarak kay\u0131tlara ge\u00e7ti. \ud83d\udd2c ER-100 Nedir? ER-100, h\u00fccrelerin ya\u015flanma s\u00fcrecinde kaybettikleri fonksiyonlar\u0131 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":277,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37,11,27],"tags":[80,81],"class_list":["post-276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genetik-muhendislik","category-haber","category-saglik-tip","tag-er-100","tag-genetik"],"_links":{"self":[{"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/posts\/276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/comments?post=276"}],"version-history":[{"count":1,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/posts\/276\/revisions"}],"predecessor-version":[{"id":278,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/posts\/276\/revisions\/278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/media\/277"}],"wp:attachment":[{"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/media?parent=276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/categories?post=276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bilimaktuel.com\/index.php\/wp-json\/wp\/v2\/tags?post=276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}